Resverlogix Corp (RVX)

Resverlogix Announces Voting Results from the 2026 Meeting of ShareholdersJune 25, 2026 9:12 PM
NewsfileCalgary, Alberta--(Newsfile Corp. - June 25, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected Five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
Votes ForVotes WithheldPercent ForPercent WithheldDonald J. McCaffrey152,172,2404,026,59097.42%2.58%Kelly McNeill152,453,2723,745,55897.60%2.40%Siu Lun (Dicky) To153,532,0062,666,82498.29%1.71%Kenneth Zuerblis153,419,2862,779,54498.22%1.78%Bradley Glass153,540,5312,658,29998.30%1.70% Resverlogix shareholders approved all resolutions outlined in the Notice of Meeting and Management Information Circular dated May 15, 2026 (the "Information Circular"). The Information Circular is available on SEDAR+ at www.sedarplus.ca, and on the Resverlogix website at www.resverlogix.com.A webcast archive of the executive presentation portion of the Meeting will be available HERE.About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).Follow us on:X.com: @Resverlogix_RVXLinkedIn: linkedin.com/company/resverlogix-corp-/Forward-Looking Statements:This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information please contact:Investor Relations
Email:

Resverlogix Closes US$2 Million Shares-for-Interest Private PlacementMay 19, 2026 5:15 PM
NewsfileCalgary, Alberta--(Newsfile Corp. - May 19, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2,760,057 (US$2,000,000) shares-for-interest private placement (the "Transaction") with an arm's length subscriber (the "Subscriber"). Under the terms of the Transaction, the Subscriber subscribed for 26,864,133 common shares at CAD$0.103 per share, equal to the applicable 5-day volume-weighted average price, for aggregate proceeds of CAD$2,760,057 (US$2,000,000). Shares acquired in the Transaction are subject to a four month hold period. After giving effect to the Transaction, the Subscriber holds approximately 7.8% of Resverlogix's common shares. The Transaction followed the settlement of CAD$2,760,057 (US$2,000,000) of accrued interest on indebtedness owing to the Subscriber by Zenith Capital Corp. ("Zenith") by way of the assignment to the Subscriber of an equal amount of indebtedness owing by Resverlogix to Zenith.The Transaction is not related to the private placement announced by Resverlogix on February 18, 2026.The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of Resverlogix's securities to, or for the account or benefit of, persons in the United States or U.S. Persons.About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).Follow us on:X.com: @Resverlogix_RVXLinkedIn: linkedin.com/company/resverlogix-corp-/Forward-Looking Statements:This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information please contact:Investor Relations
Email:

Resverlogix Announces One-Year Extension of DebentureMay 11, 2026 5:15 PM
NewsfileCalgary, Alberta--(Newsfile Corp. - May 11, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a one-year extension of the Company's US$6.0 million secured debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2027. In connection with the extension, the interest rate has been amended from 18% to 20% per annum, commencing on May 14, 2026."We appreciate Hepalink's continued support and are pleased with the one-year extension of the debenture," stated Donald McCaffrey, President & CEO of Resverlogix.About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).Follow us on:X.com: @Resverlogix_RVXLinkedIn: linkedin.com/company/resverlogix-corp-/Forward-Looking Statements:This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information please contact:Investor Relations
Email:

Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTOApril 16, 2026 7:15 AM
NewsfileCalgary, Alberta--(Newsfile Corp. - April 16, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces the revocation, effective April 15, 2026, of a management cease trade order ("MCTO") issued by the Alberta Securities Commission (the "ASC") on April 1, 2026 at the request of the Company.The Company filed its audited financial statements, management's discussion & analysis, certifications of annual filings, and annual information form for the year ended December 31, 2025 on April 10, 2026.The MCTO applied only to the Company's Chief Executive Officer and Chief Financial Officer and did not restrict trading by the general investing public.The Company confirms it is current with its disclosure obligations and anticipates complying with upcoming filing deadlines.About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).Follow us on:X.com: @Resverlogix_RVXLinkedIn: linkedin.com/company/resverlogix-corp-/Forward Looking Statements:This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information please contact:Investor Relations
Email:

Resverlogix Corp. Announces Issuance of MCTO by ASCApril 2, 2026 7:15 AM
NewsfileCalgary, Alberta--(Newsfile Corp. - April 2, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces the issuance of a management cease trade order ("MCTO") by the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), following an application made by the Company, and first announced on March 17, 2026 (the "Original Announcement"). The MCTO relates to Resverlogix's default on the prescribed deadline of March 31, 2026 (the "Default") for filing its annual audited financial statements, annual information form, and management discussion & analysis for the year ended December 31, 2025, ?as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure ??Obligations ("NI 51-102") and certification of the annual filings (collectively, the "Annual Filings").The MCTO prohibits the Company's Chief Executive Officer and Chief Financial Officer from all trading in the securities of the Company until the MCTO is revoked or varied or until two full business days after the Annual Filings are filed. The general investing public will continue to be able to trade freely in the Company's listed common shares during the term the MCTO is in effect.For additional details as to why the Annual Filings were not filed prior to the deadline, please refer to the Original Announcement, as well as the status update release on March 31, 2026. The Company and its external auditor continue to work diligently to complete the Annual Filings as soon as possible. The Company expects, but cannot assure, that the audit and the Annual Filings will be completed by April 10, 2026, and will issue a news release once the Annual Filings have been filed.?The Company has confirmed that it intends to satisfy the provisions of the alternative information guidelines described in NP 12-203 for so long as it remains in default for failure to file the Annual Filings. Further, the Company confirms that the Company is not subject to any insolvency proceedings at the time of this news release, and that since the date of the Original Announcement other than as described above, there has been no material change to the information set out in the Original Announcement that has not been generally disclosed.Until the ?Company has filed the Annual Filings, members of the Company's management and other insiders are subject to an insider trading black-out.About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).Follow us on:X.com: @Resverlogix_RVXLinkedIn: linkedin.com/company/resverlogix-corp-/Forward-Looking Statements:This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information please contact:Investor Relations
Email:

Resverlogix Corp. Provides Bi-Weekly MCTO Status UpdateMarch 31, 2026 7:09 PM
NewsfileCalgary, Alberta--(Newsfile Corp. - March 31, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") is providing an update on the management cease trade order ("MCTO") application it made to the Alberta Securities Commission (the "ASC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"). The application remains under review, and no decision has yet been made by the ASC. The Company announced on March 17, 2026 (the "Original Announcement") that it had been advised by its external auditor (the "Auditor") that the Auditor anticipated being unable to complete its audit of the ?annual financial statements by March 31, 2026. Consequently, Resverlogix will default on the prescribed deadline of March 31, 2026 (the "Default") for filing its annual audited financial statements, annual information form, and management discussion & analysis for the year ended December 31, 2025, ?as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure ??Obligations ("NI 51-102") and certification of the annual filings (collectively, the "Annual Filings").The Default resulted from unavoidable delays on the part of the Company in beginning the audit process. The Company worked with the Auditor to overcome these initial delays and assign additional resources to the audit. The Company and the Auditor continue to work diligently to complete the Annual Filings as soon as possible. The Company expects, but cannot assure, that the audit and the Annual Filings will be completed by April 10, 2026, and will issue a news release once the Annual Filings have been filed.?The ASC may grant the application and issue the MCTO or it may impose an issuer cease trade order. Should the MCTO be granted, the Company's Chief Executive Officer and Chief Financial Officer will be prohibited from all trading in the securities of the Company until such time as the Annual Filings are filed and the general investing public will continue to be able to trade freely in the Company's listed common shares during the term the MCTO is in effect.The Company confirms that since the date of the Original Announcement other than as described above, there has been no material change to the information set out in the Original Announcement that has not been generally disclosed. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 including the issuance of bi-weekly default status reports, in the form of news releases, for so long as the Company remains in default with the Annual Filings; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Annual Filings; (iii) the Company confirms that, as of the date of this news release, that the Company is not subject to any insolvency proceedings; and (iv) there is no other material information concerning the affairs of the Company that has not been generally disclosed.Until the ?Company has filed the Annual Filings, members of the Company's management and other insiders are subject to an insider trading black-out.About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions — altered by serious illnesses such as cardiovascular disease — back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).Follow us on:X.com: @Resverlogix_RVXLinkedIn: https://www.linkedin.com/company/resverlogix-corp-/Forward-Looking Statements:This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward-looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information please contact:Investor Relations
Email:

Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&AMarch 17, 2026 10:49 PM
NewsfileCalgary, Alberta--(Newsfile Corp. - March 17, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announces that because of delays in the completion of its year-end audit, the Company anticipates it will be unable to meet the prescribed deadline of March 31, 2026 for filing of the following continuous disclosure documents (collectively, the "Annual Filings"): Annual Audited Financial Statements, Annual Information Form, and Management Discussion & Analysis for the year ended December 31, 2025, ?as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure ??Obligations ("NI 51-102") and Certification of the Annual Filings;?The Company's auditor has advised the Company that it anticipates being unable to complete its audit of the ?annual financial statements by March 31, 2026.? The Company expects, but cannot assure, that the audit and the Annual Filings will be completed by April 10, 2026.?Consequently, the Company has applied to the Alberta Securities Commission (the "ASC") for a management cease trade order (the "MCTO") under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203") that, if granted, will prohibit the Company's Chief Executive Officer and Chief Financial Officer from all trading in the securities of the Company until such time as the Annual Filings are filed. No decision has yet been made by the ASC on this application. The ASC may grant the application and issue the MCTO or it may impose an issuer cease trade order in the event that the Annual Filings are delayed. Should the MCTO be granted, the general investing public will continue to be able to trade freely in the Company's listed common shares during the term the MCTO is in effect.The Company and its auditor continue to work diligently to complete the Annual Filings as soon as possible and will issue a news release once the Annual Filings have been filed. Until the Company files the Annual Filings, it will comply with the guidelines set out in NP 12-203, including the issuance of bi-weekly default status reports, in the form of news releases.Until the ?Company has filed the Annual Filings, members of the Company's management and other insiders are subject to an insider trading black-out. The Company confirms that, other than as disclosed in prior press releases and material change reports, there have been no material business developments since the November 13, 2025 filing of the Company's ?interim financial reports for the period ended September 30, 2025. About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).Follow us on:X.com: @Resverlogix_RVXLinkedIn: https://www.linkedin.com/company/resverlogix-corp-/Forward-Looking Statements:This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information, please contact:Investor Relations
Email:

Resverlogix Closes $2.8 Million Shares-for-Interest Private PlacementFebruary 18, 2026 7:00 PM
NewsfileCalgary, Alberta--(Newsfile Corp. - February 18, 2026) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") announced today that it has closed a $2.8 million shares-for-interest private placement with an immediate family member (the "Subscriber") of Resverlogix's Chairman and CEO. Under the terms of the shares-for-interest transaction, the Subscriber subscribed for 28,000,000 common shares at CAD$0.10 per share for aggregate proceeds of CAD$2.8 million. After giving effect to the transaction, the Subscriber holds approximately 9.7% of Resverlogix's common shares. The common shares are subject to a four-month hold period. The shares-for-interest transaction followed the settlement of CAD$2.8 million of accrued interest on indebtedness owing to the Subscriber by Zenith Capital Corp. ("Zenith") by way of the assignment to the Subscriber of an equal amount of accrued interest on indebtedness owing by Resverlogix to Zenith Capital Corp.The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of Resverlogix's securities to, or for the account or benefit of, persons in the United States or U.S. Persons.About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX).Follow us on:X.com: @Resverlogix_RVXLinkedIn: https://www.linkedin.com/company/resverlogix-corp-/Forward-Looking Statements:This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at www.sedarplus.ca. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.For further information please contact:Investor Relations
Email:

TA breaking 2,50 try 3 $.

No analist cover at the moment, when news came.....

Good evening clase 2,41 near high 2,47,good news and many conferences in march and april.